Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. W. Busse, E. D. Bateman, P. M. O'Byrne, J. Lötvall, A. Woodcock, H. Medley, R. Forth, L. Jacques, E. R. Bleecker (Winston-Salem, Research Triangle Park, United States Of America; Cape Town, South Africa; Hamilton, Canada; Gothenburg, Sweden; Manchester, London, United Kingdom). Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma. Eur Respir J 2013; 42: Suppl. 57, 3397

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149 Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects. Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Safety profile of ciclesonide as compared with fluticasone propionate in the treatment of children and adolescents with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004 Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012 Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone Source: International Congress 2017 – Asthma management Year: 2017 Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012